Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer

Asao Ogawa, Kyoko Kondo, Hiroyuki Takei, Daisuke Fujisawa, Yuichiro Ohe, Tatsuo Akechi

Research output: Contribution to journalArticle

Abstract

Background: The objective of this study was to assess decision-making capacity in patients newly diagnosed with lung cancer, clinical factors associated with impaired capacity, and physicians’ perceptions of patients’ decision-making capacity. Materials and Methods: We recruited 122 patients newly diagnosed with lung cancer. One hundred fourteen completed the assessment. All patients were receiving a combination of treatments (e.g., chemotherapy, chemo-radiotherapy, or targeted therapy). Decision-making capacity was assessed using the MacArthur Competence Tool for Treatment. Cognitive impairment, depressive symptoms, and frailty were also evaluated. Physicians’ perceptions were compared with the ascertainments. Results: Twenty-seven (24%, 95% confidence interval [CI], 16–31) patients were judged to have incapacity. Clinical teams had difficulty in judging six (22.2%) patients for incapacity. Logistic regression identified frailty (odds ratio, 3.51; 95% CI, 1.13–10.8) and cognitive impairment (odds ratio, 5.45; 95% CI, 1.26–23.6) as the factors associated with decision-making incapacity. Brain metastasis, emphysema, and depression were not associated with decision-making incapacity. Conclusion: A substantial proportion of patients diagnosed with lung cancer show impairments in their capacity to make a medical decision. Assessment of cognitive impairment and frailty may provide appropriate decision-making frameworks to act in the best interest of patients. Implications for Practice: Decision-making capacity is the cornerstone of clinical practice. A substantial proportion of patients with cancer show impairments in their capacity to make a medical decision. Assessment of cognitive impairment and frailty may provide appropriate decision-making frameworks to act in the best interest of patients.

Original languageEnglish
Pages (from-to)489-495
Number of pages7
JournalOncologist
Volume23
Issue number4
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Lung Neoplasms
Decision Making
Drug Therapy
Confidence Intervals
Odds Ratio
Depression
Physicians
Emphysema
Mental Competency
Radiotherapy
Therapeutics
Logistic Models
Neoplasm Metastasis
Cognitive Dysfunction
Brain

Keywords

  • Cancer
  • Decision-making capacity
  • Frailty
  • Informed consent
  • Supportive care

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer. / Ogawa, Asao; Kondo, Kyoko; Takei, Hiroyuki; Fujisawa, Daisuke; Ohe, Yuichiro; Akechi, Tatsuo.

In: Oncologist, Vol. 23, No. 4, 01.04.2018, p. 489-495.

Research output: Contribution to journalArticle

Ogawa, Asao ; Kondo, Kyoko ; Takei, Hiroyuki ; Fujisawa, Daisuke ; Ohe, Yuichiro ; Akechi, Tatsuo. / Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer. In: Oncologist. 2018 ; Vol. 23, No. 4. pp. 489-495.
@article{30bdcbb72d974f7b95db73b8a358e809,
title = "Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer",
abstract = "Background: The objective of this study was to assess decision-making capacity in patients newly diagnosed with lung cancer, clinical factors associated with impaired capacity, and physicians’ perceptions of patients’ decision-making capacity. Materials and Methods: We recruited 122 patients newly diagnosed with lung cancer. One hundred fourteen completed the assessment. All patients were receiving a combination of treatments (e.g., chemotherapy, chemo-radiotherapy, or targeted therapy). Decision-making capacity was assessed using the MacArthur Competence Tool for Treatment. Cognitive impairment, depressive symptoms, and frailty were also evaluated. Physicians’ perceptions were compared with the ascertainments. Results: Twenty-seven (24{\%}, 95{\%} confidence interval [CI], 16–31) patients were judged to have incapacity. Clinical teams had difficulty in judging six (22.2{\%}) patients for incapacity. Logistic regression identified frailty (odds ratio, 3.51; 95{\%} CI, 1.13–10.8) and cognitive impairment (odds ratio, 5.45; 95{\%} CI, 1.26–23.6) as the factors associated with decision-making incapacity. Brain metastasis, emphysema, and depression were not associated with decision-making incapacity. Conclusion: A substantial proportion of patients diagnosed with lung cancer show impairments in their capacity to make a medical decision. Assessment of cognitive impairment and frailty may provide appropriate decision-making frameworks to act in the best interest of patients. Implications for Practice: Decision-making capacity is the cornerstone of clinical practice. A substantial proportion of patients with cancer show impairments in their capacity to make a medical decision. Assessment of cognitive impairment and frailty may provide appropriate decision-making frameworks to act in the best interest of patients.",
keywords = "Cancer, Decision-making capacity, Frailty, Informed consent, Supportive care",
author = "Asao Ogawa and Kyoko Kondo and Hiroyuki Takei and Daisuke Fujisawa and Yuichiro Ohe and Tatsuo Akechi",
year = "2018",
month = "4",
day = "1",
doi = "10.1634/theoncologist.2017-0187",
language = "English",
volume = "23",
pages = "489--495",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "4",

}

TY - JOUR

T1 - Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer

AU - Ogawa, Asao

AU - Kondo, Kyoko

AU - Takei, Hiroyuki

AU - Fujisawa, Daisuke

AU - Ohe, Yuichiro

AU - Akechi, Tatsuo

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: The objective of this study was to assess decision-making capacity in patients newly diagnosed with lung cancer, clinical factors associated with impaired capacity, and physicians’ perceptions of patients’ decision-making capacity. Materials and Methods: We recruited 122 patients newly diagnosed with lung cancer. One hundred fourteen completed the assessment. All patients were receiving a combination of treatments (e.g., chemotherapy, chemo-radiotherapy, or targeted therapy). Decision-making capacity was assessed using the MacArthur Competence Tool for Treatment. Cognitive impairment, depressive symptoms, and frailty were also evaluated. Physicians’ perceptions were compared with the ascertainments. Results: Twenty-seven (24%, 95% confidence interval [CI], 16–31) patients were judged to have incapacity. Clinical teams had difficulty in judging six (22.2%) patients for incapacity. Logistic regression identified frailty (odds ratio, 3.51; 95% CI, 1.13–10.8) and cognitive impairment (odds ratio, 5.45; 95% CI, 1.26–23.6) as the factors associated with decision-making incapacity. Brain metastasis, emphysema, and depression were not associated with decision-making incapacity. Conclusion: A substantial proportion of patients diagnosed with lung cancer show impairments in their capacity to make a medical decision. Assessment of cognitive impairment and frailty may provide appropriate decision-making frameworks to act in the best interest of patients. Implications for Practice: Decision-making capacity is the cornerstone of clinical practice. A substantial proportion of patients with cancer show impairments in their capacity to make a medical decision. Assessment of cognitive impairment and frailty may provide appropriate decision-making frameworks to act in the best interest of patients.

AB - Background: The objective of this study was to assess decision-making capacity in patients newly diagnosed with lung cancer, clinical factors associated with impaired capacity, and physicians’ perceptions of patients’ decision-making capacity. Materials and Methods: We recruited 122 patients newly diagnosed with lung cancer. One hundred fourteen completed the assessment. All patients were receiving a combination of treatments (e.g., chemotherapy, chemo-radiotherapy, or targeted therapy). Decision-making capacity was assessed using the MacArthur Competence Tool for Treatment. Cognitive impairment, depressive symptoms, and frailty were also evaluated. Physicians’ perceptions were compared with the ascertainments. Results: Twenty-seven (24%, 95% confidence interval [CI], 16–31) patients were judged to have incapacity. Clinical teams had difficulty in judging six (22.2%) patients for incapacity. Logistic regression identified frailty (odds ratio, 3.51; 95% CI, 1.13–10.8) and cognitive impairment (odds ratio, 5.45; 95% CI, 1.26–23.6) as the factors associated with decision-making incapacity. Brain metastasis, emphysema, and depression were not associated with decision-making incapacity. Conclusion: A substantial proportion of patients diagnosed with lung cancer show impairments in their capacity to make a medical decision. Assessment of cognitive impairment and frailty may provide appropriate decision-making frameworks to act in the best interest of patients. Implications for Practice: Decision-making capacity is the cornerstone of clinical practice. A substantial proportion of patients with cancer show impairments in their capacity to make a medical decision. Assessment of cognitive impairment and frailty may provide appropriate decision-making frameworks to act in the best interest of patients.

KW - Cancer

KW - Decision-making capacity

KW - Frailty

KW - Informed consent

KW - Supportive care

UR - http://www.scopus.com/inward/record.url?scp=85045841283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045841283&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0187

DO - 10.1634/theoncologist.2017-0187

M3 - Article

C2 - 29212735

AN - SCOPUS:85045841283

VL - 23

SP - 489

EP - 495

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 4

ER -